Digestive health centre

References

1. Cancer Research UK. The bowel. January 2011. Available at http://www.cancerhelp.org.uk (accessed on 27 June 2012).
2. Knutson D, Greenberg G, Cronau H. Management of Crohn's disease: a practical approach. American Family Physician. 2003; 68: 707-714.
3. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53 (supplement 5): V1-V16.
4. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006; 55 (supplement 1): S36-S58.
5. Isaacs KL, Lewis JD, Sandborn WJ, et al. State of the art: IBD therapy and clinical trials in IBD. Inflammatory Bowel Diseases. 2005; 11 (supplement 1): S3-S12.
6. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504-1517.
7. Grant IR. Zoonotic potential of Mycobacterium avium spp. paratuberculosis: the current position. Journal of Applied Microbiology. 2005; 98: 1282-1293.
8. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55 (supplement 1): S1-S15.
9. Loftus EV Jr Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.
10. Cummings JR, Keshav S, Travis SP. Medical management of Crohn's disease. BMJ. 2008; 336: 1062-1066.
11. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Alimentary Pharmacology & Therapeutics. 2002; 16: 51-60.
12. Akobeng AK. Crohn's disease: current treatment options. Archives of Disease in Childhood. 2008; 93: 787-92.
13. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease: relationship between the clinical pattern and prognosis. Gastroenterology. 1985; 88: 1818-1825.
14. Newby EA, Sawczenko A, Thomas AG, et al. Interventions for growth failure in childhood Crohn's disease (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
15. Loftus EV Jr. Crohn's disease: why the disparity in mortality? Gut. 2006; 55: 447-449.
16. Mayo Clinic. Crohn's disease: complications. August 2011. Available at http://www.mayoclinic.com/health/crohns-disease/DS00104/DSECTION=complications (accessed on 27 June 2012).
17. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010; 375: 657-663.
18. British National Formulary. Non-steroidal anti-inflammatory drugs. Section 10.1.1. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 27 June 2012).
19. Rex DK, Rahmani EY, Haseman JH, et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology. 1997; 112: 17-23.
20. National Institute of Diabetes and Digestive and Kidney Diseases. Flexible sigmoidoscopy. November 2012. Available at http://digestive.niddk.nih.gov (accessed on 27 June 2012).
21. Cancer Research UK. Bowel cancer tests. October 2011. Available at http://www.cancerhelp.org.uk/type/bowel-cancer/diagnosis/bowel-cancer-tests (accessed on 27 June 2012).
22. Bowles CJ, Leicester R, Romaya C, et al. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow? Gut. 2004; 53: 277-283.
23. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
24. Benchimol EI, Seow CH, Steinhart AH, et al Traditional corticosteroids for induction of remission in Crohn's disease. In: The Cochrane Library. Wiley, Chichester, UK.
25. Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology. 1979; 77: 847-869.
26. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology. 1984; 86: 249-266.
27. Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn's disease In: The Cochrane Library. Wiley, CHichester, UK.
28. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. American Journal of Gastroenterology. 2011; 106: 590-599; quiz 600.
29. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. New England Journal of Medicine. 1994; 331: 836-841.
30. British National Formulary. Withdrawal of corticosteroids. Section 6.3.2. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http:/bnf.org (accessed on 27 June 2012).
31. Herfarth H, Gross V, Andus T, et al. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization. International Journal of Colorectal Disease. 2004; 19: 147-152.
32. British National Formulary. Side-effects of corticosteroids. Section 6.3.2. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http:/bnf.org (accessed on 27 June 2012).
33. Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology. 1993; 105: 681-691.
34. Medicines and Healthcare Products Regulatory Agency. Drug safety update: latest advice for medicines users. September 2011. Available at http://www.mhra.gov.uk (accessed on 27 June 2012).
35. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006; 55 (supplement 1): S16-S35.
36. British National Formulary. Infliximab. Section 1.5.3. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 27 June 2012).
37. National Institute for Clinical Excellence. Crohn's disease - infliximab (review) and adalimumab (review of TA40) May 2010. Technology appraisal guidance 187. Available at http://guidance.nice.org.uk/TA187 (accessed on 27 June 2012).
38. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine. 1997; 337: 1029-1035.
39. Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: a randomized-controlled trial. Alimentary Pharmacology & Therapeutics. 2006; 24: 1333-1340.
40. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117: 761-769.
41. Nahar IK, Shojania K, Marra CA, et al. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Annals of Pharmacotherapy. 2003; 37: 1256-1265.
42. U.S. Food and Drug Administration. Questions and Answers - TNF Blockers. March 2012. Available at http://www.fda.gov/ (accessed on 27 June 2012).
43. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clinical Gastroenterology and Hepatology. 2004; 2: 379-388.
44. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease: a 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scandinavian Journal of Gastroenterology. 1987; 22: 877-883.
45. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion. 1990; 45: 88-92.
46. Reese G, Smith PJ, Ford C, et al. Crohn disease. November 2011. BMJ Point of Care. Available at https://online.epocrates.com (accessed on 27 June 2012).
47. British National Formulary. Aminosalicylates. Section 1.5.1. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 27 June 2012).
48. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology. 1993; 104: 1293-1301.
49. Wright JP, Jewell DP, Modigliani R, et al. A randomized, double blind, placebo controlled trial of olsalazine for active Crohn's disease. Inflammatory Bowel Diseases. 1995; 1: 214-216.
50. British National Formulary. Inflammatory bowel disease. Section 1.5. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 27 June 2012).
51. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. New England Journal of Medicine. 1995; 332: 292-297.
52. Electronic Medicines Compendium. Methotrexate 100 mg/ml injection. 30 January 2009. Available at http://emc.medicines.org.uk (accessed on 27 June 2012).
53. British National Formulary. Methotrexate. Section 1.5.3. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 27 June 2012).
54. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
55. British National Formulary. Azathioprine. Section 1.5.3. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 27 June 2012).
56. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease (Cochrane review). In: The Cochrane Library. Update Software, Oxford, UK.
57. de Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn's disease. European Journal of Gastroenterology & Hepatology. 2004; 16: 207–212.
58. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease (Cochrane review). In: The Cochrane Library. Update software, Oxford, UK.
59. Prefontaine E, Sutherland LR, MacDonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
60. U.S. Food and Drug Administration Tumor Necrosis Factor (TNF) blockers, azathioprine and/or mercaptopurine: update on reports of hepatosplenic T-Cell lymphoma in adolescents and young adults April 2011. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ (accessed on 27 June 2012)
61. Electronic Medicines Compendium. Imuran tablets 25mg. May 2012. Available from http://emc.medicines.org.uk (accessed on 27 June 2012).
62. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Alimentary Pharmacology & Therapeutics. 2006; 23: 1117-1125.
63. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology. 2002; 123: 33-40.
64. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: result. Gastroenterology. 1982; 83: 550-562.
65. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology. 2007; 132: 2313-2319.
66. British National Formulary. Ciprofloxacin. Section 5.1.12. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 27 June 2012).
67. British National Formulary. Metronidazole. Section 5.1.11. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 27 June 2012).
68. Visapaa JP, Tillonen JS, Kaihovaara PS, et al. Lack of disulfiram-like reaction with metronidazole and ethanol. Annals of Pharmacotherapy. 2002; 36: 971-974.
69. McDonald JW, Feagan BG, Jewell D, et al. Cyclosporine for induction of remission in Crohn's disease (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
70. Jewell DP, Lennard-Jones JE, Lowes J, et al. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. European Journal of Gastroenterology & Hepatology. 1994; 6: 499-505.
71. Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. New England Journal of Medicine. 1989; 321: 845–850.
72. British National Formulary. Ciclosporin. Section 8.2.2. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 27 June 2012).
73. Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technology Assessment. 2003; 7: 1-67.
74. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. In: The Cochrane Library. Wiley, Chichester, UK.
75. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
76. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. New England Journal of Medicine. 2004; 350: 876–885.
77. Caspersen S.Elkjaer, Hansen TSW Infliximab for Inflammatory Bowel Disease in Denmark 1999-2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality Clinical Gastroenterology and Hepatology 2008; 6: 1212-1217
78. Fidder HSchnitzler, Henckaerts L,V Long-term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study Gut 2009; 58: 501-508
79. Lees CWA, Cochrane CJA, Wilson KR The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: Analysis of 620 patient-years follow-up Alimentary Pharmacology and Therapeutics 2009; 29: 286-297
80. Schneeweiss S.Korzenik Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections Alimentary Pharmacology and Therapeutics 2009; 30: 253-264
81. Vishal P, MacDonald JK, Donald-John WD, et al. Methotrexate for maintenance of remission in Crohn's disease (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
82. Vandell AG, DiPiro JT. Low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease. Pharmacotherapy. 2002; 22: 613–620.
83. Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn's disease. In: The Cochrane Library. Wiley, Chichester, UK.
84. Levine JS, Burakoff R. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. Inflammatory Bowel Diseases. 2007; 13: 1293-1298.
85. Steinhart AH, Forbes A, Mills EC, et al. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. Alimentary Pharmacology & Therapeutics. 2007; 25: 1389-1399.
86. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database of Systematic Reviews. 2010; (12): CD008870.
87. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
88. Gisbert JP, Gomollon F, Mate J, et al. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Digestive Diseases and Sciences. 2002; 47: 471–488.
89. Gordon M, Naidoo K, Thomas AG, et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews. 2011; (1): CD008414.
90. Ewe K, Herfarth C, Malchow H, Jesdinsky HJ. Postoperative recurrence of Crohn′s disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion. 1989; 42: 224–232.
91. Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. New England Journal of Medicine. 1994; 330: 1846–1851.
92. Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. Gastroenterology. 1995; 109: 774-782.
93. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn's disease (Cochrane review). In: The Cochrane Library. Update Software, Oxford, UK.
94. Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn's disease. In: The Cochrane Library. Wiley, Chichester, UK.
95. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
96. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
97. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
98. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Journal of the American Medical Association. 2006; 296: 56-63.
99. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Alimentary Pharmacology & Therapeutics. 2005; 21: 921-931.
100. Yamamoto T, Keighley MR. Smoking and disease recurrence after operation for Crohn's disease. British Journal of Surgery. 2000; 87: 398-404.
101. Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology. 2001; 120: 1093-1099.
102. Breuer-Katschinski BD, Hollander N, Goebell H. Effect of cigarette smoking on the course of Crohn's disease. European Journal of Gastroenterology & Hepatology. 1996; 8: 225-228.
103. Cunningham MF, Docherty NG, Coffey JC, et al. Postsurgical recurrence of ileal Crohn's disease: an update on risk factors and intervention points to a central role for impaired host-microflora homeostasis. World Journal of Surgery. 2010; 34: 1615-1626.
104. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. In: the Cochrane Library. Wiley, Chichester, UK.
105. Takagi S, Utsunomiya K, Kuriyama S, et al. Quality of life of patients and medical cost of "half elemental diet" as maintenance therapy for Crohn's disease: Secondary outcomes of a randomised controlled trial. Digestive and Liver Disease. 2009; 41: 390-394.
106. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease. In: The Cochrane Library. Wiley, Chichester, UK.
107. Lorenz-Meyer H, Bauer P, Nicolay C, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease: a randomized controlled multicenter trial. Scandinavian Journal of Gastroenterology. 1996; 31: 778-785.
108. Turner D, Zlotkin SH, Shah P, et al. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease (Cochrane review). In: The Cochrane Library. Wiley, CHichester, UK.
109. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. New England Journal of Medicine. 1996; 334: 1557-1560.
110. Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. Journal of the American Medical Association. 2008; 299: 1690-1697.
111. MacLean CH, Mojica WA, Newberry SJ, et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. American Journal of Clinical Nutrition. 2005; 82: 611-619.
112. Gibson GR, Rouzaud G, Brostoff J, et al. An evaluation of probiotic effects in the human gut: microbial aspects. Available at http://www.food.gov.uk/multimedia/pdfs/probioticreport.pdf (accessed on 27 June 2012).
113. Shen JRan Meta-analysis: The effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease Internal Medicine Journal 2009; 39: 103-109
114. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006; 55: 842-847.
115. Rolfe VE, Fortun PJ, Hawkey CJ, et al. Probiotics for maintenance of remission in Crohn's disease. In: The Cochrane Library. Wiley, Chichester, UK.
116. Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn's disease in the small bowel: a randomized controlled trial. Annals of Surgery. 1996; 224: 563–571.
117. Rosman AS, Melis M, Fichera A. Metaanalysis of trials comparing laparoscopic and open surgery for Crohn's disease. Surgical Endoscopy. 2005; 19: 1549-1555.
118. Tilney HS, Constantinides VA, Heriot AG, et al. Comparison of laparoscopic and open ileocecal resection for Crohn's disease: a metaanalysis. Surgical Endoscopy. 2006; 20: 1036-1044.
119. Maartense S, Dunker MS, Slors JF, et al. Laparoscopic-assisted versus open ileocolic resection for Crohn's disease: a randomized trial. Annals of Surgery. 2006; 243: 143-149.
120. Rampton DS. Management of Crohn's disease. BMJ. 1999; 319: 1480-1485.
121. Dasari BV, McKay D, Gardiner K. Laparoscopic versus Open surgery for small bowel Crohn's disease. Cochrane Database of Systematic Reviews. 2011; (1): CD006956.
122. Tekkis PP, Purkayastha S, Lanitis S, et al. A comparison of segmental vs subtotal/total colectomy for colonic Crohn's disease: a meta-analysis. Colorectal Disease. 2006; 8: 82-90.
123. Tichansky D, Cagir B, Yoo E, et al. Strictureplasty for Crohn's disease: meta-analysis. Diseases of the Colon and Rectum. 2000; 43: 911-919.
124. Shatari T, Clark MA, Yamamoto T, et al. Long strictureplasty is as safe and effective as short strictureplasty in small-bowel Crohn's disease. Colorectal Disease. 2004; 6: 438-441.
125. Reese GE, Purkayastha S, Tilney HS, et al. Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence. Colorectal Disease. 2007; 9: 686-694.

Citations